Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma

• Status: Terminated
• Trial end date: 2015-04-01

Summary

Primary objective:

· Time to progression.

Secondary objectives:

• Assess Overall survival of both treatment groups.

• Assess Tumor response rate using RECIST criteria

• Assess Toxicity profile of patients enrolled in the study.

• Exploratory evaluation of potential genetic markers of response or resistance to chemotherapy.

• Phase: Phase 3

Details

• Lead Sponsor: Spanish Lung Cancer Group
• Treatments: Cisplatin; Docetaxel; Gemcitabine